Meeting
Abstract Number: E32
SHM Converge 2022
Case Presentation: A 67-year-old woman with a history of metastatic squamous cell carcinoma of the lungs and plaque psoriasis presented with subacute pruritic and painful descaling lesions of the skin after pembrolizumab maintenance therapy (Figure 1.A). The lesions on the skin were erythematous and desquamating, worse in the upper extremities, lower extremities, abdomen, and trunk. […]
Abstract Number: L25
SHM Converge 2022
Case Presentation: An 81-year-old man with a history of paroxysmal atrial fibrillation and angiosarcoma on immunotherapy presented with acute onset of shortness of breath, chest pressure and lower extremity edema. He had been started on ipilimumab and nivolumab 1 year prior to presentation and had developed immune checkpoint inhibitor (ICI) thyroiditis, hepatitis, and pneumonitis while […]
Abstract Number: L46
SHM Converge 2022
Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]